Researchers at Spain’s CNIO and CIEMAT described a CRISPR‑based gene‑editing technique that targets tumors with amplified oncogenes, exploiting copy‑number vulnerabilities to selectively impair cancer cells. Separately, the NEO‑STIM platform reported advances in neoantigen‑specific adoptive T‑cell therapy, refining selection and expansion of tumor‑reactive T cells for personalized immunotherapy (paper slated in Nature Communications). Both developments aim to increase tumor specificity—CRISPR approaches by exploiting oncogene overload and NEO‑STIM by focusing T‑cell reactivity to patient‑specific neoantigens. These modalities address core translational challenges: delivering precision interventions that spare normal tissue and producing clinically actionable cell products. Continued preclinical validation and early clinical testing will determine their therapeutic windows and scalability.